March 12, 2014 12:30 ET | SOURCE: Regen BioPharma, Inc.
Regen BioPharma, a Majority Owned Subsidiary of Bio-Matrix Scientific Group, Provides Update on HemaXellerate I™ IND for Treatment of Drug Resistant Aplastic Anemia
March 06, 2014 14:53 ET | SOURCE: Regen BioPharma, Inc.
Bio-Matrix Scientific Group Inc. Announces Dividend Record Date to Recieve Shares in Its Subsidiary Regen BioPharma, Inc.
December 11, 2013 09:35 ET | SOURCE: Regen BioPharma, Inc.
Regen BioPharma Announces HemaXellerate I™ Efficacy Data in Animal Model of Aplastic Anemia
October 31, 2013 11:35 ET | SOURCE: Regen BioPharma, Inc.
Bio-Matrix Scientific Group’s Regen BioPharma Retains Cook General Biotechnology for Contract Manufacturing of HemaXellerate I
October 9, 2013 15:11 ET | SOURCE: Regen BioPharma, Inc.
Bio-Matrix Scientific Group Inc. Announces 20 Million Share Regen BioPharma Dividend to Be Paid to Shareholders
September 26, 2013 08:00 ET | SOURCE: Regen BioPharma, Inc.
Bio-Matrix Scientific Group’s Subsidiary Regen BioPharma Enters Into Preclinical Trials Agreement for HemaXellerate I Covering Aplastic Anemia
September 25, 2013 08:30 ET | SOURCE: Regen BioPharma, Inc.
Bio-Matrix Scientific Group’s Subsidiary Regen BioPharma Announces dCellVax Breast Cancer Immunotherapeutic Product.
September 17, 2013 | SOURCE: Regen BioPharma, Inc.
Bio-Matrix Scientific Group Recruits RNA Interference Pioneer Dr. David Suhy to Regen BioPharma Inc.’s Scientific Advisor Board
August 16, 2013 | SOURCE: Regen BioPharma, Inc.
Bio-Matrix Scientific Group Discusses Regen BioPharma’s Cancer Immunotherapy Program
August 08, 2013 08:30 ET | SOURCE: Regen BioPharma, Inc.
Regen BioPharma Inc. Licenses Cancer Gene Silencing Technology From Benitec BioPharma